Wahed Invest LLC Argenx Se Transaction History

Wahed Invest LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $16,020 - $20,319	45 Added 6.86%	701 $301,000
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $71,033 - $82,244	199 Added 43.54%	656 $258,000
Q4 2023 Mar 11, 2024	SELL	$338.91 - $506.01 $1.65 Million - $2.46 Million	-4,856 Reduced 91.4%	457 $173,000
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $1.66 Million - $2.48 Million	4,896 Added 1174.1%	5,313 $2.02 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $154,018 - $228,695	417 New	417 $205,000

403

30.8M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $36.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Wahed Invest LLC, based on Form 13F filings with the SEC.

Stay updated on Wahed Invest LLC with notifications on news.